Kidizen partners with Tea Collection to provide platform for resale of kid’s clothing, the most rapidly growing segment of the resale marketplace.
Sofia Fund
Cognition Therapeutics has a transformative 2021 with positive performance addressing age related degenerative diseases and disorders of the central nervous system.
Cognition Therapeutics Provides Update on Corporate and Pipeline Progress and Reviews Goals for 2022
PURCHASE, N.Y., Jan. 10, 2022 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina (the “Company” or “Cognition”), today provided a summary of the Company’s 2021 accomplishments and outlined upcoming milestones anticipated in the year ahead.…
Cathy Connett named to Notable Leaders in Private Equity, Investment Banking and Venture Capital List
Twin Cities Business magazine has named Sofia Fund CEO, Cathy Connett to its 2021 list of Notable Leaders in Private Equity, Investment Banking and Venture Capital List in their Dec/Jan issue.…
Sofia Fund Partner Joy Lindsay Recognized for Lifetime Achievement as Technology Investor
MINNNEAPOLIS (Nov. 17, 2021) – Sofia Fund, the angel investment firm focused exclusively on women-led companies, announces that its partner, long-term investor Joy Lindsay, has received the Lifetime Achievement Award for an outstanding career in technology from the Minnesota Technology Association (MnTech).…
Cognition Therapeutics Adds Public Company Financial and Operational Expertise to Board of Directors with Appointment of Ellen B. Richstone
PURCHASE, N.Y., Nov. 03, 2021 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina (the “Company” or “Cognition”), today announced the addition of Ellen B.…
Sofia Fund Portfolio Earns Returns as Two Portfolio Companies Move to Next Stage of Growth
Cognitive Therapeutics goes public, Explorer Surgical acquired
MINNEAPOLIS (Oct. 25, 2021) – Sofia Fund, the angel investment firm focused exclusively on women-led companies, announces new milestones: two of its portfolio companies have progressed onto their next stages of growth, providing returns for Sofia’s group of investors.…
Explorer Surgical exits Sofia Portfolio
Global Healthcare Exchange announces acquisition of Explorer Surgical, providing an opportunity for ExplORer Surgical to accelerate growth as well as immediate returns for Sofia investors. Read the GHX news release here.…
Sofia portfolio company Cognition Therapeutics goes public
Women-led biopharmaceutical company Cognition Therapeutics newly public stock started trading Oct. 8. CGTX (new NASDAQ ticker) innovates therapeutics that target age-related degenerative diseases and disorders. See the news here: https://ir.cogrx.com/news-releases/news-release-details/cognition-therapeutics-announces-pricing-upsized-initial-public…
Neurology Clinic Will Use Oculogica’s EyeBox to Detect Concussions in Patients
Sofia Fund portfolio company Oculogica signs on one of the largest neurology clinics in the U.S. to use its device.
Oculogica has been awarded a US patent to detect CTE via its eye tracking technology
This is a major innovation as CTE (chronic traumatic encephalopathy) is currently only diagnosed after death.